Evaluates pain improvement in advanced Parkinson's disease after foslevodopa/foscarbidopa infusion, suggesting effective pain management.
To evaluate change in Parkinson’s disease (PD)-related pain after initiation of 24-hour/day continuous subcutaneous infusion of foslevodopa/foscarbidopa (LDp/CDp).
No takes yet. Share an insight, caveat, or question.
Aldred et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: